Dr. Reddy's Q3FY26 Earnings Call Transcript Released
Dr. Reddy's Q3FY26 revenues grew 4.4% YoY to ₹8,727 crores, with underlying EBITDA margin at 24.8% (adjusted for a one-time provision). The India business grew 19% YoY. Semaglutide received Indian marketing authorization, with Canada launch expected Feb-May 2026. Denosumab biosimilar approved in EU/UK, but received USFDA CRL.
The earnings call transcript provides crucial financial and strategic updates, including revenue growth, pipeline progress (Semaglutide, Abatacept, Denosumab), and regulatory feedback. These details are important for investors to assess the company's performance and future outlook, impacting investment decisions.
The announcement is a transcript of an earnings call, providing detailed financial and operational updates. While there are positive developments like strong India growth and pipeline advancements, there are also challenges such as declining US generics sales, USFDA CRLs for biosimilars, and pricing pressures, leading to a neutral sentiment.
Dr. Reddy's Laboratories Limited has released the transcript of its Earnings Call conducted on January 21, 2026, for the quarter ended December 31, 2025. The call featured insights from CEO Erez Israeli and CFO M.V. Narasimham.
During the quarter, the company reported consolidated revenues of ₹8,727 crores (US$971 million), a 4.4% year-over-year growth, driven by strong performance in India, Emerging Markets, and the acquired Nicotine Replacement Therapy (NRT) business, aided by favorable forex movements. However, this was partially offset by lower Lenalidomide sales and pricing pressures in US and Europe generics.
The reported EBITDA margin was 23.5%, which included a one-time provision of ₹117 crores related to changes in employee benefit obligations under new Labour Codes in India. Adjusting for this, the underlying EBITDA margin was 24.8%. The company also noted a decline in North America Generics revenue by 16% YoY, primarily due to lower Lenalidomide sales. The India business showed robust growth of 19% YoY, with organic growth estimated between 17-18%, driven by innovative products and branded generics.
Key pipeline developments include receiving marketing authorization for Semaglutide injection in India, with potential launches in Canada between February and May 2026, and in India on March 21, 2026. The company also received European Commission and MHRA approval for its Denosumab biosimilar and launched it in Germany. However, a Complete Response Letter (CRL) was received from the USFDA for the Denosumab biosimilar BLA due to facility inspection observations.
Further, Dr. Reddy's announced Science-Based Net Zero Climate Targets, aiming for FY2045, and is a leader in CDP's Water Security and Climate Change categories. The company also entered a strategic collaboration with Immutep for the commercialization of an immunotherapy oncology drug, Eftilagimod Alfa, with an upfront payment of US$20 million and potential milestones up to US$350 million.
The company anticipates a launch for its Abatacept biosimilar in Europe around July 2027, with an addressable market of approximately US$2 billion. The NRT business showed 8% growth in constant currency terms year-on-year, with potential for upper single-digit or even double-digit growth.
What to do with a filing like this
Dr. Reddy's Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Dr. Reddy's Laboratories Limited. Read the original for the full detail.